enzalutamide or abiraterone? We would need to do randomized trials of sequential treatments to answer these questions. When the data of ECOG 3809 (randomized trial of chemotherapy- docetaxel for 6 ...

In the near future, it will be crucial to test the concomitant administration of enzalutamide and abiraterone more than the definition of the best sequence, especially in early disease stages ...

The addition of 177Lu-PSMA-617 to enzalutamide significantly improved overall survival and QOL in patients with metastatic ...

An expert discusses the therapeutic options included in the NCCN guidelines for metastatic castration-resistant prostate ...

GU ASCO annual meeting featured a prostate cancer session and a presentation by Dr. Miguel Muniz discussing outcomes for 177 Lu-PSMA-617 with and without concurrent use of androgen receptor pathway ...

Radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) more than doubled ...

With the development of the newer agents, abiraterone acetate and enzalutamide, efforts have been made to better define the basis for response and resistance. This work can be carried out in cell ...

Overall, 28% received combination therapy with ARPI (18% abiraterone; 10% apalutamide, darolutamide, or enzalutamide), 9% with DOC, and 2.5% with ARPI plus DOC. From 2017 to 2023, combined hormonal ...

The drug was more effective than the modern hormone treatments abiraterone and enzalutamide at slowing down the growth and spread of prostate cancer in patients with advanced disease, the results ...